Comparison of Focal and Conventional Verteporfin Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: To evaluate the efficacy of focal verteporfin photodynamic therapy (PDT) in patients diagnosed withchronic central serous chorioretinopathy (CSC). Methods: This study enrolled 52 eyes of 52 patients with chronic CSC who had received verteporfin PDT. Thelaser spot size of 26 eyes covering only the localized hyperfluorescent area in indocyanine green angiographywas classified as focal PDT. The PDT spot size of the other 26 eyes covered the total area of retinal pigmentepithelial detachment including the leaking point and was defined as conventional PDT. The central subfieldthickness and subfoveal choroidal thickness were measured using Heidelberg Spectralis optical coherencetomography before PDT and at months 1, 3, 6, and 12 after PDT. Results: The mean spot size of the PDT was 1,995 μm in the focal group and 2,995 μm in the conventionalgroup. Central subfield thickness steadily decreased in both groups. The mean baseline subfoveal choroidalthickness for the two groups was 334.95 and 348.35 μm, respectively, with no significant difference (p = 0.602). Subfoveal choroidal thickness decreased significantly to 304.20 μm at 1 month, 284.85 μm at 3 months,271.60 μm at 6 months, and 265.95 μm at 12 months in the focal group (p < 0.001, p < 0.001, p < 0.001, andp < 0.001, respectively, compared with baseline). In the conventional group, subfoveal choroidal thicknessdecreased significantly to 318.75, 300, 284, and 272 μm at 1, 3, 6, and 12 months, respectively (p < 0.001,p < 0.001, p < 0.001 and p < 0.001 compared with baseline). There were no significant differences betweenthe two groups in subfoveal choroidal thickness based on PDT spot size at 1, 3, 6, and 12 months (p = 0.633,p = 0.625, p = 0.676, and p =0.755, respectively). Conclusions: Focal verteporfin PDT for CSC significantly decreased the subretinal fluid and sufoveal choroidalthickness to the same extent as conventional PDT.
Abstract
Purpose: To evaluate the efficacy of focal verteporfin photodynamic therapy (PDT) in patients diagnosed withchronic central serous chorioretinopathy (CSC). Methods: This study enrolled 52 eyes of 52 patients with chronic CSC who had received verteporfin PDT. Thelaser spot size of 26 eyes covering only the localized hyperfluorescent area in indocyanine green angiographywas classified as focal PDT. The PDT spot size of the other 26 eyes covered the total area of retinal pigmentepithelial detachment including the leaking point and was defined as conventional PDT. The central subfieldthickness and subfoveal choroidal thickness were measured using Heidelberg Spectralis optical coherencetomography before PDT and at months 1, 3, 6, and 12 after PDT. Results: The mean spot size of the PDT was 1,995 μm in the focal group and 2,995 μm in the conventionalgroup. Central subfield thickness steadily decreased in both groups. The mean baseline subfoveal choroidalthickness for the two groups was 334.95 and 348.35 μm, respectively, with no significant difference (p = 0.602). Subfoveal choroidal thickness decreased significantly to 304.20 μm at 1 month, 284.85 μm at 3 months,271.60 μm at 6 months, and 265.95 μm at 12 months in the focal group (p < 0.001, p < 0.001, p < 0.001, andp < 0.001, respectively, compared with baseline). In the conventional group, subfoveal choroidal thicknessdecreased significantly to 318.75, 300, 284, and 272 μm at 1, 3, 6, and 12 months, respectively (p < 0.001,p < 0.001, p < 0.001 and p < 0.001 compared with baseline). There were no significant differences betweenthe two groups in subfoveal choroidal thickness based on PDT spot size at 1, 3, 6, and 12 months (p = 0.633,p = 0.625, p = 0.676, and p =0.755, respectively). Conclusions: Focal verteporfin PDT for CSC significantly decreased the subretinal fluid and sufoveal choroidalthickness to the same extent as conventional PDT.
참고문헌 (22)
- Piccolino FC, "Central serous chorioretinopathy and indocyanine green angiography", Retina, 14, pp.231~242 (1994)
- Yannuzzi LA, "Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy : a pilot study", Retina, 23, pp.288~298 (2003)
- Prunte C, "Choroidal capillary and venous congestion in central serous chorioretinopathy", Am J Ophthalmol, 121, pp.26~34 (1996)
- Castro-Correia J, "Longterm follow-up of central serous retinopathy in 150 patients", Doc Ophthalmol, 81, pp.379~386 (1992)
- Levine R, "Long-term follow-up of idiopathic central serous chorioretinopathy by fluorescein angiography", Ophthalmology, 96, pp.854~859 (1989)
- Loo RH, "Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy", Retina, 22, pp.19~24 (2002)
- Cardillo Piccolino F, "Photodynamic therapy for chronic central serous chorioretinopathy", Retina, 23, pp.752~763 (2003)
- Piccolino FC, "The foveal photoreceptor layer and visual acuity loss in central serous chorioretinopathy", Am J Ophthalmol, 139, pp.87~99 (2005)
- Shin JY, "Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy", Retina, 31, pp.119~126 (2011)
- Lai TY, "Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy : a short term pilot study", Br J Ophthalmol, 90, pp.869~874 (2006)
- Tsai MJ, "Half-time photodynamic therapy for central serous chorioretinopathy", Optom Vis Sci, 91, pp.1140~1145 (2014)
- Kang NH, "Change in subfoveal choroidal thickness in central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy", Eye(Lond), 27, pp.387~391 (2013)
- Smretschnig E, "Half-fluence photodynamic therapy in acute central serous chorioretinopathy", Retina, 32, pp.2014~2019 (2012)
- Chan WM, "Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy : one-year results of a randomized controlled trial", Ophthalmology, 115, pp.1756~1765 (2008)
- Son BK, "Long-term outcomes of full-fluence and half-fluence photodynamic therapy for chronic central serous chorioretinopathy", Ophthalmologica, 241, pp.105~115 (2019)
- Chan WM, "Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin : a novel treatment at the primary disease level", Br J Ophthalmol, 87, pp.1453~1458 (2003)
- Colucciello M, "Choroidal neovascularization complicating photodynamic therapy for central serous retinopathy", Retina, 26, pp.239~242 (2006)
- Chan WM, "Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy : one-year results of a prospective study", Retina, 28, pp.85~93 (2008)
- Maruko I, "Subfoveal choroidal thickness after treatment of central serous chorioretinopathy", Ophthalmology, 117, pp.1792~1799 (2010)
- Pryds A, "Choroidal thickness following extrafoveal photodynamic treatment with verteporfin in patients with central serous chorioretinopathy", Acta Ophthalmol, 90, pp.738~743 (2012)
- Maruko I, "One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy", Retina, 31, pp.1921~1927 (2011)
- Imamura Y, "Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy", Retina, 29, pp.1469~1473 (2009)